▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #39 by analyst upside · 2026-08-13
AEON
AEON Biopharma, Inc.
Healthcare · Market Cap $13M · P/E 0x
ANALYST PRICE TARGET
+1645.5%
implied upside to consensus target
Current Price $0.28
Consensus Target $4.8
Bull Target $8.4
Bear Target $1.0
Analysts Covering 3
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
3
Hold
0
Sell
0
52-Week Low $0.22
52-Week High $1.45
YTD Return -75.2%
FUNDAMENTALS
Market Cap $13M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-6.57
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.22
52-Week High $1.45
Current Price $0.28
Bear Target $1.0
Bull Target $8.4
● Now $0.28 ● Target $4.8
TRADING DATA
Avg Volume 1.3M
YTD Return -75.2%
Analyst Count 3
Consensus Buy
Upside to Target +1645.5%
Last Updated 2026-08-13

ANALYST SUMMARY

AEON Biopharma, Inc. (AEON) is currently trading at $0.28 with a Wall Street consensus price target of $4.8, implying potential upside of 1645.5% over the next 12 months. 3 analysts currently cover AEON, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $8.4, while the most cautious has a target of $1.0.

AEON operates in the Healthcare sector with a market capitalisation of $13M. The stock is down 75.2% year-to-date and is currently trading near the lower end of its 52-week range of $0.22 – $1.45.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GRI +976.9%
GRI Bio, Inc.
$3M · P/E 0.1x · Buy
ETST +854.2%
Earth Science Tech, Inc.
$30M · P/E 10.5x · Hold
PSTV +830.2%
Plus Therapeutics Inc
$27M · P/E 0.2x · Buy
DWTX +627.3%
Dogwood Therapeutics, Inc.
$65M · P/E 1.6x · Strong Buy
ATNM +508.9%
Actinium Pharmaceuticals, Inc.
$26M · P/E 2.3x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for AEON, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Aegis Capital reit
Buy → Buy 2025-10-08 Building track record
HC Wainwright & Co. reit
Buy → Buy 2024-10-01 31% win rate (48 calls)
HC Wainwright & Co. - Reiterated
Buy → Buy 2024-08-14 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-07-10 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
38
out of 100
Coverage depth
11/30
Consensus clarity
0/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →